PMID: 9183625Mar 1, 1996Paper

Prospects for antisense therapy of human leukemias

Human Cell
T Maekawa

Abstract

Recent progress in cloning of pathogenic genes and technical advance in the synthesis of antisense oligodeoxynucleotides (AS ODN) analogues have spurred a research effort dedicated to the development of antisense therapy for cancer and viral diseases. We have reported that phosphorothioate AS ODN could effectively inhibit the abnormal expression of activated or rearranged oncogenes and lead to the growth suppression of leukemic cells in vitro by the induction of apoptosis. In this article, the state of art in antisense research and the feasibility of antisense therapy for leukemia are also discussed.

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Related Papers

[Rinshō ketsueki] The Japanese journal of clinical hematology
T Maekawa
Zhonghua bing li xue za zhi Chinese journal of pathology
Xiang-hua LinLian-Huang Lu
Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology
Yong-wen HeXin-hua Liang
© 2021 Meta ULC. All rights reserved